Wilson E L, Jacobs P, Dowdle E B
Blood. 1983 Mar;61(3):568-74.
Peripheral blood cell preparation from 23 normal subjects and 72 patients with acute and 32 patients with chronic myeloid leukemia were cultured in vitro and released plasminogen activators were analyzed. The quantity of plasminogen activator secreted by leukemic cells varied widely and could not be correlated with the clinical severity of the disease. Immunochemical and electrophoretic techniques have been used to show that normal peripheral blood granulocytes released exclusively urokinase-like plasminogen activator, whereas leukemic cells secreted either urokinase or a tissue activator-like enzyme. The molecular species of enzyme released by acute myeloid leukemic cells may serve as a diagnostic marker of relevance to the management of this disease, since patients with acute myeloid leukemia whose cells released only tissue plasminogen activator did not respond to combination chemotherapy. Tissue plasminogen activators released by leukemic cells may display an unusual electrophoretic pattern that resembles that shown by urokinase. Immunochemical procedures are therefore essential for the correct identification of these enzymes.
对23名正常受试者以及72名急性髓系白血病患者和32名慢性髓系白血病患者的外周血细胞制剂进行体外培养,并对释放的纤溶酶原激活剂进行分析。白血病细胞分泌的纤溶酶原激活剂数量差异很大,且与疾病的临床严重程度无关。免疫化学和电泳技术已被用于表明,正常外周血粒细胞仅释放尿激酶样纤溶酶原激活剂,而白血病细胞则分泌尿激酶或组织激活剂样酶。急性髓系白血病细胞释放的酶的分子种类可能作为与该疾病治疗相关的诊断标志物,因为急性髓系白血病患者的细胞仅释放组织纤溶酶原激活剂时对联合化疗无反应。白血病细胞释放的组织纤溶酶原激活剂可能呈现出与尿激酶相似的异常电泳图谱。因此,免疫化学程序对于正确鉴定这些酶至关重要。